2006

Successful GMP inspections followed by manufacturing contracts

Successful GMP inspections of the Plovdiv plant were performed by Roche, sanofi~aventis, Pfizer and AstraZeneca.

The inspections confirmed the compliance of the plants with all European requirements and led to the awarding of the manufacturing of Dilatrend 6.25 mg, Dilatrend 12.5 mg, Dilatrend 25 mg (carvedilol) and Endotelon 150 mg (procyanidolic oligomers).

New products
The new additions to the product list were: AllGone (nimesulide), Antidepressa (citalopram), Cefotaxim-Tchaikapharma (cefotaxim), Co-Enalapril-Tchaikapharma (enalapril maleate/hydrochlorothiazide), Diab (gliclazide), Gliper (glimepiride), Klacar (clarithromycin), Korincare Neo (nifedipine), Lamotren (lamotrigine), Nordipin (amlodipine), Sertran (sertralin), Simvacor (simvastatin), Ticlopid (ticlopidine hydrochloride), Tonypiryn (paracetamol/ascorbic acid/chlorphenamine), Tonialgin (metamizole sodium).

Marketing contracts
Tchaikapharma was assigned the marketing authorizations for good market share medicines manufactured by Elly Lilly (Vancocin CP (vancomycin) and Axid (nizatidine).